Suppr超能文献

胃癌患者应用TC-325止血粉后发生内脏穿孔:一例报告

Visceral Perforation Following Hemostatic Powder TC-325 Application in a Patient With Gastric Cancer: A Case Report.

作者信息

Papantoniou Konstantinos, Kafentzi Theodora, Sotiropoulos Christos, Thomopoulos Konstantinos C, Konstantakis Christos

机构信息

Department of Internal Medicine, Division of Gastroenterology, Patras Medical School, University of Patras, Patras, GRC.

出版信息

Cureus. 2025 May 6;17(5):e83611. doi: 10.7759/cureus.83611. eCollection 2025 May.

Abstract

Malignant tumors of the upper gastrointestinal (GI) tract are a common cause of GI bleeding, often presenting therapeutic challenges due to diffuse hemorrhage and poor visualization. Local hemostatic agents, such as TC-325 (Hemospray; Winston-Salem, NC: Cook Medical), have emerged as effective bridging therapies prior to definitive treatment. However, visceral perforation, though rare, is a serious complication associated with TC-325 use. We present a case of an 87-year-old male with metastatic gastric adenocarcinoma who experienced visceral perforation following TC-325 application for recurrent upper GI bleeding. Despite achieving initial hemostasis, the patient succumbed to complications of perforation. This study highlights the need for caution when using TC-325 in patients with advanced malignancies and friable tissue.

摘要

上消化道(GI)恶性肿瘤是GI出血的常见原因,由于弥漫性出血和视野不佳,常常带来治疗挑战。局部止血剂,如TC-325(Hemospray;北卡罗来纳州温斯顿 - 塞勒姆:库克医疗公司),已成为确定性治疗前有效的过渡治疗方法。然而,内脏穿孔虽然罕见,但却是与使用TC-325相关的严重并发症。我们报告一例87岁男性转移性胃腺癌患者,在应用TC-325治疗复发性上消化道出血后发生内脏穿孔。尽管最初实现了止血,但患者最终死于穿孔并发症。本研究强调在晚期恶性肿瘤和组织脆弱的患者中使用TC-325时需要谨慎。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/86b0/12141772/5a7915f3b442/cureus-0017-00000083611-i01.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验